The Highthroughput Screening (HTS) partnership has been established by the Academic Drug Discovery Consortium (ADDC) and AstraZeneca. They are looking for applications from institutions performing drug discovery who are interested in high quality screening compounds provided by AstraZeneca.
The screening library will be provided free-of-charge to selected proposals. Funding to support the screen and the follow-up chemistry needs to be provided by the center or by external sources.
The deadline for Requests for Proposals is 1st September 2014.
Areas of Interest: (click here for more information)
- Cardiovascular & Metabolic Disease (CVMD)
- Respiratory, Inflammation & Autoimmune (RIA)
- Personalized Healthcare (PHC)